The European Group for Blood and Marrow Transplantation (EBMT) risk score provides a simple tool to assess instantly chances and risks of hematopoietic SCT(HSCT) for an individual patient pre-transplant. Five factors, age of the patient, stage of the disease, time from diagnosis, donor type and donor recipient gender combination augment risk for an individual patient with increasing score from 0 as best to 7 as worst in an additive way. The score holds for all acquired hematological disorders, for allogeneic and autologous HSCT (score 0-5), is independent of the HSCT technology and is valid for standard or reduced intensity conditioning. Survival is uniformly worse for older patients, transplanted in advanced disease stage after a long-time interval and with a mismatched donor than for younger patients, transplanted soon in early stage with a well matched donor. Additional risk factors such as performance score, CMV serostatus or cytokine polymorphisms improve prediction but to different extents for low or high-risk patients. Comparative assessment of disease risk and global pre-transplant risk should guide decisions for each patient with his/her specific disease between HSCT and a non-transplant approach and replace the traditional 'donor vs no donor' with such a risk-adapted individualized strategy.
risk assessment; EBMT risk score
The 'old' CML risk score
The EBMT risk score was introduced more than 10 years ago for patients with CML, the most frequent indication for an allogeneic HSCT at that time (Table 1) . 1, 2 It was based on previous analyses that showed that patient age, disease stage, donor type and donor recipient gender combination had an impact on outcome. [3] [4] [5] [6] Specifically, an early EBMT analysis on outcome after an allogeneic HSCT showed almost overlapping survival curves for patients with acute myeloid, acute lymphoblastic and chronic myeloid leukemia when disease stage was considered, limiting the role of biological differences between the different leukemias. 7, 8 The EBMT risk score went one step ahead at that time and gave a clear result. Each of the five pre-transplant risk factors was important on its own but all added to the overall risk. No risk factor annihilated the others. Outcome after an allogeneic HSCT was no longer erratic but could be predicted with reasonable accuracy. TRM increased in a stepwise pattern with increasing risk score, survival decreased correspondingly.
This was an essential element at that time in the decision making process between allogeneic HSCT and drug treatment with IFN alpha and hydroxyurea. 9 The challenge for transplant physicians and patients alike was to decide between procedures with an inherent high risk of early mortality but the perspectives for cure and a treatment with minimal early mortality and morbidity but an absolute risk of late transformation and death. The data from the EBMT risk score analysis showed that the risk of the transplant procedure would increase while waiting. Early transplantation in early disease stage was associated with the best possible long-term outcome. As we will see below, such considerations hold true today for all acquired hematological disorders.
The EBMT risk score for CML was repeatedly confirmed and validated by independent national and international studies. [10] [11] [12] The risk score was shown to be predictive for CML patients treated with myeloablative or reduced intensity conditioning, transplanted with BM or peripheral blood as well as with T-cell depleted or T-cell replete graft products. The score is valid independent of the pretreatment and holds even today with tyrosine kinase inhibitors as primary treatment. [13] [14] [15] Patients transplanted at an older age, in a more advanced disease stage, after a longer time interval from diagnosis with a donor other than an HLA identical sibling donor and with a female donor for a male recipient had uniformly a worse outcome compared with younger patients, transplanted still in first chronic phase within 1 year from diagnosis from an HLA identical sex-matched sibling donor.
Impact on survival was stepwise despite the recognition that some factors were concordant while others were discordant with non-relapse mortality and relapse risk. Both, non-relapse mortality and relapse risk increased with increasing age, increasing disease stage and increasing time interval. In contrast, non-relapse mortality increased with donors other than an HLA identical sibling and with a female donor for a male recipient, but relapse risk decreased in these settings. However, the detrimental effects of the increased incidence and severity of GvHD never outweighed the potential benefits of the associated GvL. Hence, survival decreased stepwise with increasing risk score, due to both, increasing non-relapse mortality and increasing relapse risk with increasing risk score.
Extension of the risk score
Earlier analyses on outcome after HSCT for other diseases indicated, that age, disease stage, time interval, donor type and donor recipient gender combinations influence survival, non-relapse mortality and relapse risk. [16] [17] [18] [19] [20] This suggested that the role of the combined risk factors should also be tested to evaluate the predictive role of the EBMT risk score in other acquired malignant and non-malignant hematological disorders. An extensive analysis of the EBMT mega file on more than 50 000 allogeneic HSCT over a time period of more than 10 years confirmed the hypothesis (Figure 1 ). 21 The EBMT risk score was associated with non-relapse mortality, relapse risk and survival after an allogeneic HSCT for AML, ALL, MDS, MPS, NHL, MM and AA ( Figure 2 ). As shown before for patients with CML, patients transplanted at an older age, in a more advanced disease stage, after a longer time interval from diagnosis with a donor other than an HLA identical sibling donor and a female donor for a male recipient had a uniformly worse outcome compared with younger patients, transplanted still in early disease after a short time interval from diagnosis from an HLA identical sex-matched sibling donor. The same stepwise pattern of the risk score was observed in all disease categories examined.
The same analysis showed that the risk score had its association with all three outcomes, non-relapse mortality, relapse risk and survival, for patients transplanted with reduced or standard conditioning, with T-cell depleted or T-cell replete graft products and with BM or peripheral blood as stem cell source. Non-relapse mortality was always higher with a higher EBMT risk score and survival correspondingly lower with increasing score, regardless of the technology used. This does not mean that the technology itself has no impact on outcome. Non-relapse mortality at 3 years was lower with reduced intensity conditioning in all risk categories and relapse rate higher. Survival in contrast remained similar for patients transplanted with standard or reduced intensity conditioning when compared with the same pre-transplant risk profile.
This extension of the EBMT risk score to other disease categories was validated by the most recent EBMT analysis on the role of the JACIE accreditation process on outcome. 22 It was confirmed in all disease categories, for all teams regardless of their JACIE accreditation status and for teams in high, middle or low income countries by World ). Bank Category. Furthermore, the analysis was extended to more than 100 000 patients with an autologus HSCT. It showed that patients treated with autologous HSCT at an older age, in a more advanced disease stage, after a longer time interval from diagnosis had a uniformly worse outcome compared with younger patients, transplanted still in early disease after a short time interval from diagnosis. The hazard ratio for failure, as assessed in a multivariate and clustered analysis, increased stepwise with each additional risk score point. Interestingly, the hazard for non-relapse mortality increased relatively more with increasing score for patients with an autologous than for those with an allogeneic HSCT ( Figure 3 ).
Effects of the five pre-transplant risk factors

Patient age
Patient age is a universal predictor of outcome in almost all diseases and treatment forms. It is not unique to HSCT. It applies to transplant and non-transplant treatment strategies. Older patients suffer from more complications, have a longer recuperation period and tolerate drugs differently and less well than younger patients. 23 The risk score divides age in three categories, below age of 20 years (0 score points), between 20 and 40 years of age (1 score point) and above 40 years (2 score points). This was reasonable at the time of its introduction when very few patients over the age of 60 were transplanted. The age brackets were chosen on purpose, to ease assessment, despite the fact that the impact of age cannot correctly be broken into three categories only. Influence of age on outcome is J-shaped, with higher non-relapse mortality for infants and very young children. It increases after age 2-5 in a near linear mode. Hence, the age risk factor is not the same for a 21-year old as for a 39-year old patient, despite its numerical identical value of 1 scoring point. The score gives an estimate. The correct age might tip the balance in the final evaluation toward or against the transplant decision for an individual patient. Probably, the age brackets have to be supplemented by an additional score point for patients above age 60; the respective studies have yet to be performed.
The influence of age on outcome is seen in all disease categories, in autologous and allogeneic HSCT and for all transplant technologies with some differences. Age appears to be of greater importance for patients with aplastic anemia than for patients with lymphoproliferative disorders. The introduction of reduced intensity conditioning has opened access to allogeneic HSCT for older patients, but has not changed the fact that mortality is higher for older patients than for younger patients given the same reduced or standard intensity conditioning.
Disease stage
The initial EBMT risk score categorized disease stage into the traditional CML disease classification: chronic phase (0 score points), accelerated phase (1 score point) and blast crisis (2 score points). It had to be adapted slightly for CML, limiting early disease to first chronic phase and advanced disease stage to blast crisis. The intermediate disease stage now includes all other disease stages, for example, 2nd or 3rd chronic phase or first and later accelerated phase. It has been extended to the other acquired hematological diseases. Early disease stage (0 score points) includes AL transplanted in first CR, MDS transplanted untreated or in first CR, CML in first chronic phase, and NHL and MM transplanted either untreated or in first CR. Intermediate disease stage (1 score point) includes AL in second CR, CML at all other stages than first chronic phase or blast crisis, MDS in second CR or in PR, lymphoma and multiple myeloma in second CR, in PR 
Time interval from diagnosis to transplant
The key question for patients with CML at the time of the EBMT risk score evaluation was: Can I wait some years, observe response to therapy and decide for a transplant if response to therapy fails? Several analyses showed consistently that time interval was an independent risk factor. Non-relapse mortality and relapse risk increased with increasing time from diagnosis to transplant. The reasons for the increased non-relapse mortality, despite same disease stage, same donor type and same procedure remain still a matter of debate. The cutoff of 1 year did provide a reasonable break into two categories, less than 1 year (0 score points) and more than 1 year (1 score point). Again, it is not an all or nothing breakpoint. Outcome is even better with a time interval shorter than 1 year; it worsens after the 1-year breakpoint with increasing duration. As for the other risk factors, a relatively shorter or longer interval within the score bracket can be used to tip the decision.
There is one caveat with the time intervals. Time interval from diagnosis to transplant cannot be used for patients transplanted in first remission of any disease. The score is always arbitrarily set as 0 for patients transplanted in first remission. Earlier analyses have shown that the time interval from diagnosis to transplant is subdivided into two periods with discordant influence on outcome. 24 A longer time interval from diagnosis to first remission is associated with increasing risk of non-relapse mortality and decreased survival after a subsequent HSCT. Poor response to initial induction treatment might reflect a disease with an inherent higher risk profile. The more treatment required to achieve remission might add to pre-transplant toxicity. In contrast, a longer time interval from first remission to transplant is associated with a lower risk of relapse, a lower risk of non-relapse mortality and an improved survival after subsequent HSCT. Patients with high-risk disease and early relapse, therefore a short time interval from remission to transplant, are excluded from the group with a long time interval, and have therefore changed the patient mix of this category. Some patients with a long waiting time in remission might indeed already be cured and are no longer at risk of relapse. In addition, a longer time interval from first remission to transplant might give more time to regenerate and to reduce the toxic cytokine load. Therefore, the composite time interval, diagnosis to transplant without information on the two subparts is of no value for patients in first remission.
More evaluations are needed to integrate time interval better for AML, MDS and NHL, where time interval in a Cox regression analysis is less predictive ( Table 2) . Selection of very high-risk patients by criteria other than stage in the early time interval explains in part this only discrepancy of the score. It can be taken into account in the evaluation. It does not change the general overall information, that for patients with otherwise equal risks, survival decreases with a longer time from diagnosis.
Donor type
The initial EBMT risk score discriminated between a HLAidentical sibling as donor (0 score points) and an unrelated donor (1 score point). The few twin donor transplants were neglected, haploidentical transplants were very rare and most unrelated donor transplants were matched by six Ag, tested by serology or low-resolution typing. Outcome after an allogeneic HSCT from an unrelated donor was undisputedly worse than after an HLA identical sibling donor HSCT. It is interesting to note in this context, that the donor type impact is not the same in all disease categories, with the highest impact in aplastic anemia, and the lowest in ALL. The EBMT risk score A Gratwohl
Today, the situation is changed. HLA typing has advanced with high-resolution typing and more than 14 million unrelated volunteer donors are available. Outcome of a transplant with a 12/12 high-resolution Ag matched unrelated donor is better than that of a poorly matched donor. [25] [26] [27] It is also discussed by some groups that in certain situations a young very well matched donor might yield better outcome than an old HLA identical sibling donor. 28 It is an imprecise approach to include haploidentical and cord blood transplants in the same 'non-HLA identical sibling donor' category. Still, survival was consistently better for all risk categories and all diseases with the HLA identical sibling donor. 21, 22 The degree of matching might again help to decide in favor or against the transplant in the final assessment for an individual patient.
Donor recipient gender combination
The role of H-Y encoded mHA in allogeneic HSCT was recognized very early in the history of HSCT. 6 Female recipients with aplastic anemia of a male allogeneic stem cell product had a higher risk of rejection; antibodies and cellular reactions against H-Y encoded Ag could be documented in vitro. Male recipients of female stem cells in contrast showed a higher incidence and severity of acute and chronic GvHD as well as lower risk of relapse. This was confirmed in multiple clinical and experimental models. 17, [28] [29] [30] [31] It is of interest to note in this context, that female recipients of a male kidney show a higher rejection rate as well. 32 The initial EBMT risk score for CML showed the additive effect of the donor recipient gender combination with a two brackets distribution of 'all other combinations' (0 score points) and 'female donor for a male recipient' (1 score point). The role of the donor recipient gender combination was documented in all other disease categories as well. A female donor for a male recipient is always associated with higher non-relapse mortality, a lower relapse risk but a lower OS. The impact of the female donor for the male recipient on outcome was different in different disease categories. The effect was highest in CML and lowest in ALL (Table 2) .
Relative weight of the individual risk factors
The scores of 1 for each risk category was an approximation already for the initial EBMT risk score for CML. It remains even more of an approximation when all different hematological disease categories are evaluated. The relative weight varies between the different diseases ( Table 2) . Age class has the highest effect in patients with aplastic anemia, a moderate effect in patients with NHL. Disease stage has a marked effect in all diseases with, not surprisingly, the highest risk increase in CML. Time interval has the strongest effect for patients with aplastic anemia, it could not be documented for patients with NHL. The donor other than an HLA identical sibling had the strongest effect in aplastic anemia. The donor recipient gender combination had the highest impact in CML, a lower impact in ALL, AML and MDS. The effect was not the same for all risk categories. The additional detrimental effect of a female donor for a male recipient becomes negligible for patients in very advanced disease. 29 Despite these limitations and despite the varying relative weight, the overall predictive value of the simple risk score was strong. In a ROC AUC analysis of the combined effects of all risk factors over all disease categories and comparing the detailed Cox analysis with the simplified risk score the results were comforting. The explanatory content of the detailed Cox analysis was only minimally higher (0.634) than that of the simple risk score (0.621). 21 Knowledge of the relative impact of the individual risks in the specific disease helps in the final analysis, but the overall risk score retains its primary value as a rapid and instant tool for basic assessment.
Combination with other risk factors
Risk assessment for an individual patient is complicated, many known and even more unknown pre-transplant, peritransplant and post-transplant factors influence outcome. The EBMT risk score explains at best 63% of the outcome (Table 2) . Pre-transplant factors are given at the time of the transplant, they have to be included in the decision making process between transplant now, at a later stage of the disease or not at all. They relate to the patient, his or her disease and to the donor. Peri-transplant factors can be influenced by the transplant team. They include the transplant techniques, conditioning, GvHD prevention or choice of stem cell source. Post-transplant risk factors, mainly presence or absence of GvHD or of relapse are unknown at the time of the transplant; they cannot be chosen for by the transplant team but influence outcome. They explain why even the best pre-transplant assessment never will capture and predict all post-transplant events.
Pre-transplant risk factors have additive effects on survival, but their impact is not uniform and depends on the sum of the risks. Some factors become negligible with increasing risks, others predominant. Survival is always about 3-5% worse for CMV seropositive patients compared with CMV seronegative patients for low but not for very high-risk patients (risk score 5-7). 21, 33 Hence, the additional influence of CMV serostatus becomes negligible in high-risk patients (Figure 4) . In contrast, the role of Karnofsky performance score becomes increasingly important with increasing risk score ( Figure 5) . 21, 34 A poor performance score has few additional negative effects in low-risk patients. It has a deleterious effect in patients with a high EBMT risk score, rendering a transplant procedure obsolete in such conditions. Similar analyses have looked at the influence of one or more HLA-incompatibilities in unrelated HSCT. The benefit of optimal matching is highest in low-risk patients. [25] [26] [27] 35, 36 
Consequences and outlook
There are no direct formal randomized studies, comparing allogeneic HSCT with a non-transplant strategy. Most studies investigated a donor vs no donor comparison on an intention to treat analysis. Patients with a HLA identical
The EBMT risk score A Gratwohl sibling donor were considered as transplants, patients with no donor as no transplants. Based on such analyses, guidelines recommend for instance allogeneic HSCT for patients with intermediate and high-risk AML in first remission, not for patients with good risk AML. 23, 28, 37, 38 This simplistic view probably needs to be changed. Such analyses consider disease risk; they fail to integrate the adjusted transplant risk of the individual patient. The simplified algorithm should be replaced with the question whether, for a patient with a given disease and its given disease risk profile, at a given time in the treatment course, with a given donor and a given extended EBMT risk profile, HSCT provides a better outcome than a nontransplant strategy at the same time point. The answer then will be different for a 30-year-old CMV seronegative male patient with low-risk AML in first CR, with no co morbidities, excellent performance score and a HLA identical brother compared with a 30-year-old CMV seropositive male patient with the same low-risk AML but with some co morbidities and a HLA identical sister as donor. Similar considerations should be integrated continuously into the treatment strategy from diagnosis on. Continuous risk assessment of the disease in parallel to risk assessment of the transplant procedure should dominate the decision to perform or not to perform a transplant and about the time point.
Such a risk-adapted strategy is possible today but implies initiation of a donor search at diagnosis and a continuous risk assessment. 39 The reluctance to change to such a strategy is twofold. For many teams and groups, numbers in their own series are too small to document the risk score profile in sufficient clarity. A rare patient with EBMT risk score 0 might die, a rare patient with risk score 7 might survive and influence patient and physicians strategy considerations more than statistical clarity from large numbers. This applies even more so in most recent times with markedly improved outcomes in general and when early outcome during the initial hospitalization time is more vivid. 40 Second, change to a continuous risk assessment implies stringent cooperation between the primary care providers and the transplant teams in the respective countries, sometimes a difficult task. It can be rendered even more complicated with current strategies from Health Care providers when they ask for presentation of center specific public outcome data. Such presentations and comparisons are frequently flawed by non-standardized and skewed risk populations. Presentation of data by risk score and Used with permission from Gratwohl et al.
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The EBMT risk score A Gratwohl specified time point of analyses might present a more objective approach. 41, 42 The same considerations for adjusted risk assessment will apply to all acquired hematological disease categories, including aplastic anemia, lymphoma or multiple myeloma. The current 'donor vs no donor' or 'transplant yes or no for this indication' evaluations fail to provide an optimal strategy for individual patients. Current strategies do not consider early allogeneic HSCT even for high-risk myeloma patients. 43 They assume, derived from donor vs no donor analyses, that outcome of allogeneic HSCT is worse for patients with MM than for those with AML. A riskadjusted analysis fails to support this supposition. Patients with multiple myeloma in the EBMT analyses had a median 2 score points higher risk score than patients with AML. 21 The general feeling of worse outcome is correct. This is not due to the disease but to the skewed risk profile distribution. There is no indication that a patient with myeloma and standard or reduced-intensity conditioning has a different outcome from a patient with AML and the same EBMT risk score.
In summary, all analyses so far indicate, that pretransplant risk elements act additively for an individual patient. This is the key message of the EBMT risk score. This information needs to be integrated in the risk assessment and should be used to decide for or against the transplant and should guide in the selection of the optimal transplant technique and the appropriate time point. Integration of the risk profile into the decision process will ultimately lead to a better selection of the transplant patients. It will lead to earlier HSCT for one; evidently also withhold a transplant procedure from another patient with a better outcome without HSCT or with a minimal chance for success. Such an individualized risk-based approach will ultimately lead to a better outcome for all patients.
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